Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Trial on the Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes

Next Previous
X
Search
Trial Profile

Randomized Controlled Trial on the Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sitagliptin (Primary) ; Insulin; Insulin aspart; Insulin glargine; Insulin lispro; Metformin/sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Sita-Hospital

    • Most Recent Events

    • 12 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 14 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
    • 22 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top